Vonoprazan Fumarate (TAK-438) CAS 1260141-27-2 881681-01-2 API High Quality

Short Description:

Chemical Name: Vonoprazan Fumarate (TAK-438)

CAS: 1260141-27-2; 881681-01-2

Assay: 98.0~102.0%

Appearance: White or Almost-White Crystalline Powder

API High Quality, Commercialized Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name Vonoprazan Fumarate
Synonyms TAK-438
CAS Number 1260141-27-2; 881681-01-2 
CAT Number RF-API99
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C21H20FN3O6S
Molecular Weight 461.463
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White or Almost-White Crystalline Powder
Identification 1 H-NMR Consistent with the Standard
Identification IR The IR Absorption spectrum of the sample concordant with reference standard
Identification HPLC The retention time of the sample concordant with reference standard
Water Content ≤0.50%
Residue on Ignition ≤0.20%
Heavy Metals (as Pb) ≤20ppm
Related Substances
Impurity A ≤0.20%
Impurity B ≤0.15%
Impurity C ≤0.15%
Any Other Impurity ≤0.10%
Total Impurities ≤1.0%
Residual Solvents
Methanol ≤0.30%
Ethanol ≤0.50%
Ethyl Acetate ≤0.50%
Assay / Analysis Method 98.0%~102.0% (By HPLC)
Test Standard Enterprise Standard
Usage API

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture.

Advantages:

1

FAQ:

Application:

Vonoprazan Fumurate (TAK-438) (CAS: 1260141-27-2; 881681-01-2), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate (Takecab), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014. Vonoprazan Fumarate is mainly used for the treatment of helicobacter pylori infection, gastroesophageal reflux, peptic ulcer, duodenal ulcer, esophagitis, gastric ulcer and other gastric acid related diseases. The product has a strong, lasting inhibition of gastric acid secretion. At the treatment dose, Vonoprazan Fumarate has little effect on other enzymes and little effect on physiological functions of the body. It is safe and more tolerable. 

  • Write your message here and send it to us